| [1] |
Goldhrirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009 [J]. Ann Oncol,2009,20(8):1319-1329.
|
| [2] |
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Ann Oncol.2011,22(8):1736-1747.
|
| [3] |
Perou CM,Sorlie T,Eisen MB,et al. Molecular portraits of human breast tumors [J]. Nature,2000,406(6797):747-752.
|
| [4] |
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression pattern of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci,2001,98(19):10 869-10 874.
|
| [5] |
Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis [J]. Mod Pathol,1998,11(2):155-168.
|
| [6] |
Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer [J]. J Clin Oncol, 1999, 17(5):1474-1481.
|
| [7] |
Kurosumi M. Immunohistochemical assessment of hormone receptor status using a new scoring system (J-Score) in breast cancer [J]. Breast Cancer,2007,14(2):189-193.
|
| [8] |
Hammond MEH, Hayes DF, Dowsett M, et al. American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol,2010,28(16):2784-2795.
|
| [9] |
Slamon DJ,Clark GM. Amplification of C-ERB-B2 and aggressive breast tumors [J]. Science,1988,240(4860):1795-1798.
|
| [10] |
De Potter CR. The neu oncogene: more than a prognostic indicator? [J]. Hum Pathol,1994,25(12):1264-1268.
|
| [11] |
Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer [J]. J Natl Cancer Inst,1998,90(18):1346-1360.
|
| [12] |
Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer [J]. J Natl Cancer Inst,2004,96(15):1141-1151.
|
| [13] |
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med,2001,344(11):783-792.
|
| [14] |
The Japanese Breast Cancer Society. New HER2 testing guideline, 3rd Edition[EB/OL]. http:/ /www. jbcs. gr. jp/HER2henkou/HER2.pdf#search='トラスツズマブ病理部会'.
|
| [15] |
Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. J Clin Oncol,2007,25(30):118-145.
|
| [16] |
Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol,1984,133(4):1710-1715.
|
| [17] |
Viale G, Giobbie Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from breast international group trial 1-98 comparing adjuvant tamoxifen with letrozole [J]. J Clin Oncol,2008,26(34):5569-5575.
|
| [18] |
Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma [J]. Cancer,2000,89(11):2145-2152.
|
| [19] |
Tamaki K, Moriya T, Sato Y, et al. Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis [J]. Cancer Sci,2009,100(1):88-94.
|
| [20] |
Miyashita M, Ishida T, Ishida K, et al. Histopathological subclassification of triple negative breast cancer using prognostic system: five variables as candidates [J]. Virchows Arch,2011,458(1):65-72.
|
| [21] |
Moriya T, Kasajima A, Ishida K, et al. New trends of immunohistochemistry for making differential diagnosis of breast lesions [J]. Med Mol Morphol,2006,39(1):8-13.
|